31
Views
20
CrossRef citations to date
0
Altmetric
Review

Telomeres and telomerase: targets for cancer chemotherapy?

&
Pages 1567-1586 | Published online: 25 Feb 2005
 

Abstract

Telomerase is a specialised ribonucleoprotein comprising of, at present, 3 known components: the human telomerase RNA component (hTR); the human telomerase reverse transcriptase catalytic subunit (hTERT), and TP1, a telomerase-associated protein. Applications involving telomerase have been proposed in the fields of cellular engineering, diagnostics/prognostics and therapeutics. In the diagnostics area, around 85% of human cancers have been shown to possess telomerase activity, while such activity is not detectable in most somatic cells. In some cases (notably neuroblastomas, gastric and breast tumours), higher levels of telomerase activity were associated with poor prognosis. Telomerase activity, which has generally been measured using a highly sensitive PCR-based TRAP assay, may also be assessed to monitor residual disease following surgery and/or chemotherapy. As telomerase appears to be selectively expressed in tumours versus normal cells, many have proposed that the enzyme represents a good target for inhibition. Efforts are underway to target various components of the telomerase/telomere machinery including the hTR template region using antisense oligonucleotides and peptide nucleic acids (PNAs), some of which inhibit at the nanomolar level, hTERT, and the telomere/telomerase interaction. Small-molecule inhibitors of telomerase have recently been described. These include a series of regioisomeric diamidoanthracene-9,10-diones (the best of which inhibit telomerase in cell-free assays with IC50 values of 1 - 5 μM) and porphyrin-based molecules. These molecules have been proposed to act via stabilisation of guanine-quadruplexes, structures associated with telomeres and telomerase. Reverse transcriptase inhibitors, such as AZT triphosphate, have also been shown to inhibit telomerase. This will clearly be an area where, in the near future, potent inhibitors will be developed thus permitting further target validation experiments to be performed in tumour-bearing mice and ultimately in cancer patients.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.